52214-84-3 | Ciprofibrate

Packsize	Purity	Availability	Price	Discounted Price
250mg	95%	in stock	$16.00	$11.00
1g	95%	in stock	$19.00	$13.00
5g	95%	in stock	$36.00	$25.00
25g	95%	in stock	$90.00	$63.00
100g	95%	in stock	$251.00	$176.00
500g	95%	in stock	$760.00	$532.00

Description

• Catalog Number: AI51716
• Chemical Name: Ciprofibrate
• CAS Number: 52214-84-3
• Molecular Formula: C13H14Cl2O3
• Molecular Weight: 289.1545
• MDL Number: MFCD00467135
• SMILES: OC(=O)C(Oc1ccc(cc1)C1CC1(Cl)Cl)(C)C
• NSC Number: 759617

Computed Properties

• Complexity: 333
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 18
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• Undefined Atom Stereocenter Count: 1
• XLogP3: 3.4

Literature

• Differential Regulation of Gene Expression by Cholesterol Biosynthesis Inhibitors That Reduce (Pravastatin) or Enhance (Squalestatin 1) Nonsterol Isoprenoid Levels in Primary Cultured Mouse and Rat Hepatocytes.

  The Journal of pharmacology and experimental therapeutics 20160801

• Identification of modulators of the nuclear receptor peroxisome proliferator-activated receptor α (PPARα) in a mouse liver gene expression compendium.

  PloS one 20150101

• Identification of chemical modulators of the constitutive activated receptor (CAR) in a gene expression compendium.

  Nuclear receptor signaling 20150101

• Fish oil and fenofibrate prevented phosphorylation-dependent hepatic sortilin 1 degradation in Western diet-fed mice.

  The Journal of biological chemistry 20140808

• A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.

  Toxicological sciences : an official journal of the Society of Toxicology 20140101

• Role of Peroxisome Proliferator-Activated Receptor β/δ and B-Cell Lymphoma-6 in Regulation of Genes Involved in Metastasis and Migration in Pancreatic Cancer Cells.

  PPAR research 20130101

• Hormonal and chemical regulation of paraoxonases in mice.

  The Journal of pharmacology and experimental therapeutics 20120901

• Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii.

  Bioorganic & medicinal chemistry letters 20120401

• Conservation and divergence of chemical defense system in the tunicate Oikopleura dioica revealed by genome wide response to two xenobiotics.

  BMC genomics 20120101

• PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways.

  PPAR research 20120101

• Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study.

  Cardiovascular diabetology 20120101

• The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes.

  PPAR research 20120101

• Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data.

  PloS one 20120101

• AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells.

  PPAR research 20120101

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Mechanisms of cardiovascular remodeling in hyperhomocysteinemia.

  Antioxidants & redox signaling 20111001

• Ciprofibrate quantification in human plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry for pharmacokinetic studies.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110815

• Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease.

  Experimental cell research 20110701

• Nutritional and metabolic status of HIV-positive patients with lipodystrophy during one year of follow-up.

  Clinics (Sao Paulo, Brazil) 20110301

• Animal models to study the role of long-term hypergastrinemia in gastric carcinogenesis.

  Journal of biomedicine & biotechnology 20110101

• Megalin/LRP2 expression is induced by peroxisome proliferator-activated receptor -alpha and -gamma: implications for PPARs' roles in renal function.

  PloS one 20110101

• Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.

  The open cardiovascular medicine journal 20110101

• Biological responses to perfluorododecanoic acid exposure in rat kidneys as determined by integrated proteomic and metabonomic studies.

  PloS one 20110101

• Walnut oil increases cholesterol efflux through inhibition of stearoyl CoA desaturase 1 in THP-1 macrophage-derived foam cells.

  Nutrition & metabolism 20110101

• Rhabdomyolysis associated with fenofibrate monotherapy in a patient with chronic myelogenous leukemia.

  Case reports in gastroenterology 20110101

• Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators.

  The open medicinal chemistry journal 20110101

• Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.

  Lipids in health and disease 20110101

• CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes.

  The Journal of clinical endocrinology and metabolism 20101201

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Role of Esrrg in the fibrate-mediated regulation of lipid metabolism genes in human ApoA-I transgenic mice.

  The pharmacogenomics journal 20100601

• Effect of a Large Dose of Di (2-ethylhexyl) phthalate (DEHP) on Hepatic Peroxisome in Cynomolgus Monkeys (Macaca Fascicularis).

  Journal of toxicologic pathology 20100601

• Transcription coactivator PBP/MED1-deficient hepatocytes are not susceptible to diethylnitrosamine-induced hepatocarcinogenesis in the mouse.

  Carcinogenesis 20100201

• Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

  European heart journal 20100101

• Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists induce constitutive androstane receptor (CAR) and cytochrome P450 2B in rat primary hepatocytes.

  Drug metabolism and pharmacokinetics 20100101

• PPARalpha: energy combustion, hypolipidemia, inflammation and cancer.

  Nuclear receptor signaling 20100101

• Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia.

  Vascular health and risk management 20100101

• Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.

  Vascular health and risk management 20100101

• Coactivators in PPAR-Regulated Gene Expression.

  PPAR research 20100101

• Molecular Mechanisms and Genome-Wide Aspects of PPAR Subtype Specific Transactivation.

  PPAR research 20100101

• PPARα in Obesity: Sex Difference and Estrogen Involvement.

  PPAR research 20100101

• Methods of chromatographic determination of medicines decreasing the level of cholesterol.

  Acta poloniae pharmaceutica 20100101

• PRIC295, a Nuclear Receptor Coactivator, Identified from PPARα-Interacting Cofactor Complex.

  PPAR research 20100101

• Role of PPARα in Hepatic Carbohydrate Metabolism.

  PPAR research 20100101

• Peroxisome proliferator-activated receptor alpha target genes.

  PPAR research 20100101

• Gene Expression Profiling in Wild-Type and PPARα-Null Mice Exposed to Perfluorooctane Sulfonate Reveals PPARα-Independent Effects.

  PPAR research 20100101

• Effects of the PPARα Agonist and Widely Used Antihyperlipidemic Drug Gemfibrozil on Hepatic Toxicity and Lipid Metabolism.

  PPAR research 20100101

• Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting.

  Lipids in health and disease 20100101

• PPARs and xenobiotic-induced adverse effects: relevance to human health.

  PPAR research 20100101

• Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report.

  European journal of clinical pharmacology 20091201

• Subacute exposure to N-ethyl perfluorooctanesulfonamidoethanol results in the formation of perfluorooctanesulfonate and alters superoxide dismutase activity in female rats.

  Archives of toxicology 20091001

• Regulation of CYP4A expression by bezafibrate in primary culture of rat and human hepatocytes: interspecies difference and influence of N-acetylcysteine.

  Toxicology in vitro : an international journal published in association with BIBRA 20091001

• Probing the fibrate binding specificity of rat liver fatty acid binding protein.

  Journal of medicinal chemistry 20090910

• Antidiabetic action of bezafibrate in a large observational database.

  Diabetes care 20090401

• Induction of mouse UDP-glucuronosyltransferase mRNA expression in liver and intestine by activators of aryl-hydrocarbon receptor, constitutive androstane receptor, pregnane X receptor, peroxisome proliferator-activated receptor alpha, and nuclear factor erythroid 2-related factor 2.

  Drug metabolism and disposition: the biological fate of chemicals 20090401

• Cancer biomarker AKR1B10 and carbonyl metabolism.

  Chemico-biological interactions 20090316

• Differential regulation of peroxisome proliferator-activated receptor (PPAR)-alpha1 and truncated PPARalpha2 as an adaptive response to fasting in the control of hepatic peroxisomal fatty acid beta-oxidation in the hibernating mammal.

  Endocrinology 20090301

• Activation of hepatic lipase expression by oleic acid: possible involvement of USF1.

  Nutrients 20090201

• Differences in transcriptional activation by the two allelic (L162V Polymorphic) variants of PPARα after Omega-3 fatty acids treatment.

  PPAR research 20090101

• Systems biology for identifying liver toxicity pathways.

  BMC proceedings 20090101

• Peroxisome proliferator-activated receptors in HCV-related infection.

  PPAR research 20090101

• Safety and efficacy of rosiglitazone in the elderly diabetic patient.

  Vascular health and risk management 20090101

• Kidney function and estimated vascular risk in patients with primary dyslipidemia.

  The open cardiovascular medicine journal 20090101

• Regulation of bile acid and cholesterol metabolism by PPARs.

  PPAR research 20090101

• Hypothyroidism enhances tumor invasiveness and metastasis development.

  PloS one 20090101

• Regulation of sulfotransferase and UDP-glucuronosyltransferase gene expression by the PPARs.

  PPAR research 20090101

• Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver.

  Lipids in health and disease 20090101

• Sensitivity of liver metabolism in jerboa (Jaculus orientalis) to ciprofibrate, a peroxisome proliferator.

  Molecular medicine reports 20090101

• Induction of hepatic glutathione S-transferases in male mice by prototypes of various classes of microsomal enzyme inducers.

  Toxicological sciences : an official journal of the Society of Toxicology 20081201

• Species-specific kinetics and zonation of hepatic DNA synthesis induced by ligands of PPARalpha.

  Toxicological sciences : an official journal of the Society of Toxicology 20080701

• Role of the p50 subunit of NF-kappaB in vitamin E-induced changes in mice treated with the peroxisome proliferator, ciprofibrate.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20080601

• Administration of ciprofibrate to lactating mothers induces PPARalpha-signaling pathway in the liver and kidney of suckling rats.

  Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20080601

• Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.

  European journal of pharmacology 20080428

• Design, synthesis, biological evaluation and docking studies of pterostilbene analogs inside PPARalpha.

  Bioorganic & medicinal chemistry 20080401

• Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.

  International journal of cardiology 20080227

• Ciglitazone induces caspase-independent apoptosis via p38-dependent AIF nuclear translocation in renal epithelial cells.

  Toxicology 20080203

• Update on the use of fibrates: focus on bezafibrate.

  Vascular health and risk management 20080201

• High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease.

  Vascular health and risk management 20080201

• Peroxisome proliferator-activated receptor alpha agonists enhance cardiomyogenesis of mouse ES cells by utilization of a reactive oxygen species-dependent mechanism.

  Stem cells (Dayton, Ohio) 20080101

• Tissue distribution, ontogeny, and regulation of aldehyde dehydrogenase (Aldh) enzymes mRNA by prototypical microsomal enzyme inducers in mice.

  Toxicological sciences : an official journal of the Society of Toxicology 20080101

• Peroxisome proliferator activated receptors and lipoprotein metabolism.

  PPAR research 20080101

• PPAR Agonists and Cardiovascular Disease in Diabetes.

  PPAR research 20080101

• Pigment epithelium-derived factor is an angiogenesis and lipid regulator that activates peroxisome proliferator-activated receptor alpha.

  Advances in experimental medicine and biology 20080101

• Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders.

  PPAR research 20080101

• Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006.

  PloS one 20080101

• The Role of PPARs in Cancer.

  PPAR research 20080101

• Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.

  Arzneimittel-Forschung 20080101

• The Role of PPAR Ligands in Controlling Growth-Related Gene Expression and their Interaction with Lipoperoxidation Products.

  PPAR research 20080101

• PPAR Alpha Regulation of the Immune Response and Autoimmune Encephalomyelitis.

  PPAR research 20080101

• PPAR Regulation of Inflammatory Signaling in CNS Diseases.

  PPAR research 20080101

• The Role of PPARs in the Endothelium: Implications for Cancer Therapy.

  PPAR research 20080101

• The Role of NF-kappaB in PPARalpha-Mediated Hepatocarcinogenesis.

  PPAR research 20080101

• Development and Validation of RP-HPLC Method for Simultaneous Estimation of Atorvastatin Calcium and Fenofibrate in Tablet Dosage Forms.

  Indian journal of pharmaceutical sciences 20080101

• Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARalpha agonists.

  Bioorganic & medicinal chemistry letters 20071215

• Induction of nuclear translocation of constitutive androstane receptor by peroxisome proliferator-activated receptor alpha synthetic ligands in mouse liver.

  The Journal of biological chemistry 20071214

• Importance of hepatic induction of constitutive androstane receptor and other transcription factors that regulate xenobiotic metabolism and transport.

  Drug metabolism and disposition: the biological fate of chemicals 20071001

• Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration.

  Toxicology and applied pharmacology 20070915

• Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI.

  Journal of lipid research 20070801

• Transcriptional regulation of Cidea, mitochondrial cell death-inducing DNA fragmentation factor alpha-like effector A, in mouse liver by peroxisome proliferator-activated receptor alpha and gamma.

  The Journal of biological chemistry 20070622

• The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.

  Current medical research and opinion 20070501

• P450 CYP2C epoxygenase and CYP4A omega-hydroxylase mediate ciprofibrate-induced PPARalpha-dependent peroxisomal proliferation.

  Journal of lipid research 20070401

• Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels.

  Vascular health and risk management 20070201

• Temporal dynamics of gene expression in the lung in a baboon model of E. coli sepsis.

  BMC genomics 20070101

• PPARs, Obesity, and Inflammation.

  PPAR research 20070101

• Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.

  American journal of therapeutics 20070101

• Clofibrate treatment in pigs: effects on parameters critical with respect to peroxisome proliferator-induced hepatocarcinogenesis in rodents.

  BMC pharmacology 20070101

• A Three Stage Integrative Pathway Search (TIPS) framework to identify toxicity relevant genes and pathways.

  BMC bioinformatics 20070101

• Identification of genes that regulate multiple cellular processes/responses in the context of lipotoxicity to hepatoma cells.

  BMC genomics 20070101

• Radiation injury is a potentially serious complication to fluoroscopically-guided complex interventions.

  Biomedical imaging and intervention journal 20070101

• Consumption costs of inappropriate medicines estimated from bulk purchase data: The example of NSAids in Guatemala.

  International journal of clinical pharmacology and therapeutics 20061101

• Activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) induces cell death through MAPK-dependent mechanism in osteoblastic cells.

  Toxicology and applied pharmacology 20060901

• Key issues in the role of peroxisome proliferator-activated receptor agonism and cell signaling in trichloroethylene toxicity.

  Environmental health perspectives 20060901

• Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha.

  Toxicological sciences : an official journal of the Society of Toxicology 20060801

• Effects of ciprofibrate on testicular and adrenal steroidogenic enzymes in the rat.

  Reproductive toxicology (Elmsford, N.Y.) 20060701

• Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome.

  British journal of clinical pharmacology 20060601

• Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.

  International journal of nanomedicine 20060601

• PRIC320, a transcription coactivator, isolated from peroxisome proliferator-binding protein complex.

  Biochemical and biophysical research communications 20060505

• Separation of fibrate-type antihyperlipidemic drugs by capillary electrophoresis and their quantitation in pharmaceuticals.

  Journal of pharmaceutical and biomedical analysis 20060503

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Inhibition of hepatocarcinogenesis by the deletion of the p50 subunit of NF-kappaB in mice administered the peroxisome proliferator Wy-14,643.

  Toxicological sciences : an official journal of the Society of Toxicology 20060401

• Workgroup report: Review of genomics data based on experience with mock submissions--view of the CDER Pharmacology Toxicology Nonclinical Pharmacogenomics Subcommittee.

  Environmental health perspectives 20060401

• Paullinia pinnata extracts rich in polyphenols promote vascular relaxation via endothelium-dependent mechanisms.

  Journal of cardiovascular pharmacology 20060401

• Cytochrome P450 Cyp4x1 is a major P450 protein in mouse brain.

  The FEBS journal 20060301

• [Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].

  Investigacion clinica 20060301

• Characterization of liver function in transdifferentiated hepatocytes.

  Journal of cellular physiology 20060101

• Flow cytometric assessment of peroxisome proliferation from frozen liver of fibrate-treated monkeys.

  International journal of toxicology 20060101

• [AIP--atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice].

  Vnitrni lekarstvi 20060101

• Gene expression profiles in rat liver slices exposed to hepatocarcinogenic enzyme inducers, peroxisome proliferators, and 17alpha-ethinylestradiol.

  International journal of toxicology 20060101

• Examination of Ligand-Dependent Coactivator Recruitment by Peroxisome Proliferator-Activated Receptor-alpha (PPARalpha).

  PPAR research 20060101

• Ciprofibrate stimulates the gastrin-producing cell by acting luminally on antral PPAR-alpha.

  American journal of physiology. Gastrointestinal and liver physiology 20051201

• Optimal lipid modification: the rationale for combination therapy.

  Vascular health and risk management 20051201

• Fibrates inhibit aldose reductase activity in the forward and reverse reactions.

  Biochemical pharmacology 20051125

• Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate.

  AIDS (London, England) 20051104

• Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver.

  Toxicological sciences : an official journal of the Society of Toxicology 20051101

• Differential associations of statin and fibrate treatment with carotid arterial remodeling.

  American journal of hypertension 20051101

• Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways.

  Drug metabolism and disposition: the biological fate of chemicals 20050901

• Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates.

  Journal of cardiovascular pharmacology 20050901

• Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia.

  Journal of neuroscience research 20050801

• Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver.

  Drug metabolism and disposition: the biological fate of chemicals 20050701

• Induction of pancreatic acinar cell proliferation by thyroid hormone.

  The Journal of endocrinology 20050601

• Differences in cell proliferation in rodent and human hepatic derived cell lines exposed to ciprofibrate.

  Cancer letters 20050526

• Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters.

  Journal of agricultural and food chemistry 20050504

• Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor.

  Molecular pharmacology 20050401

• Study of the liquid chromatography retention of some fibrate-type antihyperlipidemic drugs on C18 and CN columns: application for quantitation in pharmaceutical formulations.

  Journal of AOAC International 20050101

• [A case of Parkinsonian syndrome, cognitive impairment and hyperammonemia induced by divalproate sodium prescribed for bipolar disorder].

  L'Encephale 20050101

• The effect of ciprofibrate on flow-mediated dilation and inflammatory markers in patients with combined hyperlipidemia.

  Endothelium : journal of endothelial cell research 20050101

• Single and chronic administration of ciprofibrate or of ciprofibrate-glycinate in male Fischer 344 rats: comparison of the effects on morphological and biochemical parameters in liver and blood.

  European journal of drug metabolism and pharmacokinetics 20050101

• Plasmalogens in rat liver chromatin: new molecules involved in cell proliferation.

  Journal of cellular physiology 20041201

• Application of comparative functional genomics to identify best-fit mouse models to study human cancer.

  Nature genetics 20041201

• Peroxisome proliferator-activated receptors as regulators of lipid metabolism; tissue differential expression in adipose tissues during cold acclimatization and hibernation of jerboa (Jaculus orientalis).

  Biochimie 20041101

• Activation of peroxisome proliferator-activated receptor alpha in rat spinal cord after peripheral noxious stimulation.

  Neuroscience letters 20041007

• Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I.

  The Journal of pharmacology and experimental therapeutics 20041001

• The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia.

  Atherosclerosis 20041001

• Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys.

  Carcinogenesis 20040901

• PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells.

  Regulatory peptides 20040815

• Effects of vitamin E on the NF-kappaB pathway in rats treated with the peroxisome proliferator, ciprofibrate.

  Toxicology and applied pharmacology 20040815

• Effects of peroxisome proliferator-activated receptor alpha activation on pathways contributing to cholesterol homeostasis in rat hepatocytes.

  Biochimica et biophysica acta 20040705

• The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.

  The Journal of biological chemistry 20040702

• Visualization and quantitation of peroxisomes using fluorescent nanocrystals: treatment of rats and monkeys with fibrates and detection in the liver.

  Toxicological sciences : an official journal of the Society of Toxicology 20040701

• Peroxisome proliferator activated receptors alpha and gamma require zinc for their anti-inflammatory properties in porcine vascular endothelial cells.

  The Journal of nutrition 20040701

• Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity.

  Journal of cardiovascular pharmacology and therapeutics 20040601

• Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease.

  Journal of immunology (Baltimore, Md. : 1950) 20040501

• Characterization of the species-specificity of peroxisome proliferators in rat and human hepatocytes.

  Toxicological sciences : an official journal of the Society of Toxicology 20040401

• Peroxisome proliferator-activated receptor alpha (PPARalpha) activators induce hepatic farnesyl diphosphate synthase gene expression in rodents.

  The Journal of steroid biochemistry and molecular biology 20040201

• Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation.

  Nutrition journal 20040101

• Miniaturized fluorescent RNA dot blot method for rapid quantitation of gene expression.

  BMC biotechnology 20040101

• Application of UV-derivative spectra for determination of four antihyperlipidaemic drugs in pharmaceutical formulations.

  Acta poloniae pharmaceutica 20040101

• Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study).

  Cardiovascular diabetology 20040101

• The levels of soluble adhesion molecules in diabetic and nondiabetic patients with combined hyperlipoproteinemia and the effect of ciprofibrate therapy.

  Angiology 20040101

• Overexpression of SR-BI by adenoviral vector reverses the fibrateinduced hypercholesterolemia of apolipoprotein E-deficient mice.

  The Journal of biological chemistry 20031226

• Cell proliferation and apoptosis are altered in mice deficient in the NF-kappaB p50 subunit after treatment with the peroxisome proliferator ciprofibrate.

  Toxicological sciences : an official journal of the Society of Toxicology 20031001

• Hypertriglyceridemia increases mitochondrial resting respiration and susceptibility to permeability transition.

  Journal of bioenergetics and biomembranes 20031001

• Liver gene expression in rats in response to the peroxisome proliferator-activated receptor-alpha agonist ciprofibrate.

  Physiological genomics 20030929

• The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E.

  The Biochemical journal 20030801

• Chromatin sphingomyelin changes in cell proliferation and/or apoptosis induced by ciprofibrate.

  Journal of cellular physiology 20030801

• Lipid-lowering drugs and serum liver enzymes: the effects of body weight and baseline enzyme levels.

  Fundamental & clinical pharmacology 20030801

• Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.

  The Journal of clinical endocrinology and metabolism 20030801

• [Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates].

  Casopis lekaru ceskych 20030801

• Fibrates and renal function.

  Clinical nephrology 20030701

• LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit?

  Diabetes research and clinical practice 20030701

• Changes of peroxisomal fatty acid metabolism during cold acclimatization in hibernating jerboa (Jaculus orientalis).

  Biochimie 20030701

• [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20030701

• Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells.

  The Journal of pharmacology and experimental therapeutics 20030601

• Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.

  Acta cardiologica 20030601

• Fibrates and their newly synthesized glycinate or glycinate-methylester derivatives: comparison of the interactions with liver cytochrome P450 dependent monooxygenase- and oxidase-functions in vitro.

  Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20030601

• [Ciprofibrate-induced acute cholestatic hepatitis].

  Annales d'endocrinologie 20030601

• Molecular profiling of hepatocellular carcinomas developing spontaneously in acyl-CoA oxidase deficient mice: comparison with liver tumors induced in wild-type mice by a peroxisome proliferator and a genotoxic carcinogen.

  Carcinogenesis 20030501

• Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.

  Naunyn-Schmiedeberg's archives of pharmacology 20030301

• Antral G cells in rats during dosing with a PPAR alpha agonist: a morphometric and immunocytochemical study.

  Medical electron microscopy : official journal of the Clinical Electron Microscopy Society of Japan 20030301

• The hypolipidemic drug metabolites nafenopin-CoA and ciprofibroyl-CoA are competitive P2Y1 receptor antagonists.

  FEBS letters 20030211

• Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice.

  The Biochemical journal 20030201

• Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia.

  American journal of physiology. Lung cellular and molecular physiology 20030201

• Fibrates and C-reactive protein.

  Clinica chimica acta; international journal of clinical chemistry 20030201

• Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation.

  Blood 20030115

• Different effects of the liver mitogens triiodo-thyronine and ciprofibrate on the development of rat hepatocellular carcinoma.

  Toxicologic pathology 20030101

• [Conjugation reactions of ciprofibrate with human and laboratory animals].

  Arzneimittel-Forschung 20030101

• Hibernation impact on the catalytic activities of the mitochondrial D-3-hydroxybutyrate dehydrogenase in liver and brain tissues of jerboa (Jaculus orientalis).

  BMC biochemistry 20030101

• Effects of various fibrates on serum alkaline phosphatase activity.

  Atherosclerosis 20021101

• Peroxisome proliferators compete and ameliorate Hcy-mediated endocardial endothelial cell activation.

  American journal of physiology. Cell physiology 20021001

• Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.

  Journal of cardiovascular pharmacology and therapeutics 20021001

• PPAR alpha stimulates the rat gastrin-producing cell.

  Molecular and cellular endocrinology 20020930

• Differentiated properties of hepatocytes induced from pancreatic cells.

  Hepatology (Baltimore, Md.) 20020901

• Human apical sodium-dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor alpha.

  The Journal of biological chemistry 20020823

• Chronic hydroxymethylglutaryl coenzyme a reductase inhibition and endothelial function of the normocholesterolemic rat: comparison with angiotensin-converting enzyme inhibition.

  Journal of cardiovascular pharmacology 20020801

• HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells.

  Clinical science (London, England : 1979) 20020801

• Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor alpha.

  The Journal of steroid biochemistry and molecular biology 20020701

• Mechanism of constrictive vascular remodeling by homocysteine: role of PPAR.

  American journal of physiology. Cell physiology 20020501

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• The peroxisome proliferator-activated receptor alpha-selective activator ciprofibrate upregulates expression of genes encoding fatty acid oxidation and ketogenesis enzymes in rat brain.

  Neuropharmacology 20020401

• Cytochemical and biochemical demonstration of an ATPase in membranes of human peroxisomes.

  The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 20020301

• Synergistic effect of 4-hydroxynonenal and PPAR ligands in controlling human leukemic cell growth and differentiation.

  Free radical biology & medicine 20020201

• Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.

  Journal of cardiovascular risk 20020201

• Alteration of liver cell function and proliferation: differentiation between adaptation and toxicity.

  Toxicologic pathology 20020101

• Effect of ciprofibrate on C-reactive protein and fibrinogen levels.

  Angiology 20020101

• Prevention/reversal of choline deficiency-induced steatohepatitis by a peroxisome proliferator-activated receptor alpha ligand in rats.

  In vivo (Athens, Greece) 20020101

• Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia.

  Current medical research and opinion 20020101

• Use of dominant negative nuclear receptors to study xenobiotic-inducible gene expression in primary cultured hepatocytes.

  Journal of pharmacological and toxicological methods 20020101

• The transcription of the peroxisome proliferator-activated receptor alpha gene is regulated by protein kinase C.

  Toxicology letters 20011215

• Nafenopin-, ciprofibroyl-, and palmitoyl-CoA conjugation in vitro: kinetic and molecular characterization of marmoset liver microsomes and expressed MLCL1.

  Archives of biochemistry and biophysics 20011201

• Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.

  International journal of clinical pharmacology and therapeutics 20011201

• Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.

  Journal of cardiovascular pharmacology 20011101

• Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression.

  Arteriosclerosis, thrombosis, and vascular biology 20011101

• Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.

  Metabolism: clinical and experimental 20011101

• Fibrate-induced increase in blood urea and creatinine.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010701

• Fibrate treatment can increase serum creatinine levels.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010601

• Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.

  Metabolism: clinical and experimental 20010601

• [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].

  Orvosi hetilap 20010415

• Impressive lipid changes following hypolipidaemic drug administration can unveil subclinical hyperthyroidism.

  Diabetes, obesity & metabolism 20010401

• Homocysteine elevation with fibrates: is it a class effect?

  The Israel Medical Association journal : IMAJ 20010401

• Statin-fibrate combinations in patients with combined hyperlipedemia.

  Atherosclerosis 20010301

• Differential induction of stearoyl-CoA desaturase and acyl-CoA oxidase genes by fibrates in HepG2 cells.

  Biochemical pharmacology 20010201

• Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20001201

• Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.

  International journal of cardiology 19990601

• Insulin differentially affects xenobiotic-enhanced, cytochrome P-450 (CYP)2E1, CYP2B, CYP3A, and CYP4A expression in primary cultured rat hepatocytes.

  The Journal of pharmacology and experimental therapeutics 19990501

• Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha.

  Blood 19990501

• Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.

  Thrombosis and haemostasis 19981201

• Mechanisms of peroxisome proliferation by perfluorooctanoic acid and endogenous fatty acids.

  General pharmacology 19980801

• Clinical pharmacokinetics of fibric acid derivatives (fibrates).

  Clinical pharmacokinetics 19980201

• Activation of hepatic NF-kappaB by the herbicide Dicamba (2-methoxy-3,6-dichlorobenzoic acid) in female and male rats.

  Journal of biochemical and molecular toxicology 19980101

• Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12,13-myristate-type tumor promoters in immortalized mouse liver cells.

  The Journal of biological chemistry 19970207

• Peroxisome proliferators alter the expression of estrogen-metabolizing enzymes.

  Biochimie 19970101

• Growth regulation by peroxisome proliferators: opposing activities in early and late G1.

  Cancer research 19960715

• Oltipraz-mediated changes in aflatoxin B(1) biotransformation in rat liver: implications for human chemointervention.

  Cancer research 19960515

• Flow cytometric analysis of neoplastic nodules and hepatocellular carcinomas induced by ciprofibrate in the rat.

  British journal of cancer 19960101

• [Rhabdomyolysis and unexplained malaise. Role of combination of ciprofibrate and norfloxacin].

  La Revue de medecine interne 19960101

• Currently available hypolipidaemic drugs and future therapeutic developments.

  Bailliere's clinical endocrinology and metabolism 19951001

• The effects of diquat and ciprofibrate on mRNA expression and catalytic activities of hepatic xenobiotic metabolizing and antioxidant enzymes in rat liver.

  Toxicology and applied pharmacology 19950901

• Xenobiotic-enhanced expression of cytochrome P450 2E1 and 2B1/2B2 in primary cultured rat hepatocytes.

  Drug metabolism and disposition: the biological fate of chemicals 19950701

• The herbicide dicamba (2-methoxy-3,6-dichlorobenzoic acid) is a peroxisome proliferator in rats.

  Fundamental and applied toxicology : official journal of the Society of Toxicology 19950601

• Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element.

  The Journal of biological chemistry 19941209

• Effect of the peroxisome proliferators ciprofibrate and perfluorodecanoic acid on hepatic cell proliferation and toxicity in Sprague-Dawley rats.

  Carcinogenesis 19941201

• Antihyperlipidaemic agents. Drug interactions of clinical significance.

  Drug safety 19941101

• A recombinant phenobarbital-inducible rat liver UDP-glucuronosyltransferase (UDP-glucuronosyltransferase 2B1) stably expressed in V79 cells catalyzes the glucuronidation of morphine, phenols, and carboxylic acids.

  Molecular pharmacology 19940101

• Analysis of activated protooncogenes in B6C3F1 mouse liver tumors induced by ciprofibrate, a potent peroxisome proliferator.

  Carcinogenesis 19930101

• Mechanism of action of fibrates.

  Postgraduate medical journal 19930101

• Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.

  Biochimica et biophysica acta 19920709

• Loss of peroxisomal enzyme expression in preneoplastic and neoplastic lesions induced by peroxisome proliferators in rat livers.

  Carcinogenesis 19920201

• Plasma levels of HGF in rats treated with tumor promoters.

  Carcinogenesis 19920101

• Effect of different hypolipemic agents on rat liver peroxisomal and mitochondrial functions and biogenesis.

  Cellular and molecular biology 19910101

• Peroxisome proliferation in neoplastic nodules and hepatocellular carcinomas induced by ciprofibrate in the rat.

  Experimental pathology 19910101

• On the mechanism of the hepatocarcinogenicity of peroxisome proliferators.

  Chemico-biological interactions 19910101

• Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.

  Journal of clinical pharmacology 19910101

• Characterization of the hepatic responses to the short-term administration of ciprofibrate in several rat strain. Co-induction of microsomal cytochrome P-450 IVA1 and peroxisome proliferation.

  Biochemical pharmacology 19900901

• Peroxisome proliferator-induced alterations in the expression and modification of rat hepatocyte plasma membrane proteins.

  Cancer research 19900201

• Reversible alteration in the expression of the gap junctional protein connexin 32 during tumor promotion in rat liver and its role during cell proliferation.

  Cancer communications 19900101

• Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.

  Arteriosclerosis (Dallas, Tex.) 19890101

• Lack of expression of glutathione-S-transferase P, gamma-glutamyl transpeptidase, and alpha-fetoprotein messenger RNAs in liver tumors induced by peroxisome proliferators.

  Cancer research 19880901

• Interactions of inhibitors of carnitine palmitoyltransferase I and fibrates in cultured hepatocytes.

  The Biochemical journal 19880701

• Absence of gamma-glutamyltranspeptidase activity in lung metastasis in rats with hepatocellular carcinomas induced by ciprofibrate, a peroxisome proliferator.

  Cancer letters 19871201

• Peroxisome proliferator-induced hepatocarcinogenesis: levels of activating and detoxifying enzymes in hepatocellular carcinomas induced by ciprofibrate.

  Carcinogenesis 19870101